KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Stereotaxis (STXS) Research & Development (2016 - 2025)

Stereotaxis (STXS) has disclosed Research & Development for 16 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development rose 3.75% to $2.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.5 million, a 3.06% increase, with the full-year FY2024 number at $9.8 million, down 4.99% from a year prior.
  • Research & Development was $2.5 million for Q3 2025 at Stereotaxis, up from $1.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.9 million in Q2 2022 to a low of $1.8 million in Q2 2025.
  • A 5-year average of $2.5 million and a median of $2.5 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: surged 37.43% in 2021, then fell 21.82% in 2025.
  • Stereotaxis' Research & Development stood at $2.6 million in 2021, then fell by 8.22% to $2.4 million in 2022, then fell by 7.83% to $2.2 million in 2023, then rose by 26.13% to $2.8 million in 2024, then decreased by 8.75% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for STXS's Research & Development are $2.5 million (Q3 2025), $1.8 million (Q2 2025), and $2.4 million (Q1 2025).